Implantable theranostic device for in vivo real-time NMR evaluation of drug impact in brain tumors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 Feb 2024
24 Feb 2024
Historique:
received:
01
11
2023
accepted:
21
02
2024
medline:
25
2
2024
pubmed:
25
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
The evaluation of the efficacy of a drug is a fundamental step in the development of new treatments or in personalized therapeutic strategies and patient management. Ideally, this evaluation should be rapid, possibly in real time, easy to perform and reliable. In addition, it should be associated with as few adverse effects as possible for the patient. In this study, we present a device designed to meet these goals for assessing therapeutic response. This theranostic device is based on the use of magnetic resonance imaging and spectroscopy for the diagnostic aspect and on the application of the convection-enhanced delivery technique for the therapeutic aspect. The miniaturized device is implantable and can be used in vivo in a target tissue. In this study, the device was applied to rodent glioma models with local administration of choline kinase inhibitor and acquisition of magnetic resonance images and spectra at 7 Tesla. The variations in the concentration of key metabolites measured by the device during the administration of the molecules demonstrate the relevance of the approach and the potential of the device.
Identifiants
pubmed: 38402370
doi: 10.1038/s41598-024-55269-1
pii: 10.1038/s41598-024-55269-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4541Subventions
Organisme : Agence Nationale de la Recherche
ID : TRAIL ANR-10-LABX-57
Organisme : Agence Nationale de la Recherche
ID : ANR SEMB
Informations de copyright
© 2024. The Author(s).
Références
Parrish, K. E., Sarkaria, J. N. & Elmquist, W. F. Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier. Clin. Pharmacol. Ther. 97, 336–346 (2015).
pubmed: 25669487
doi: 10.1002/cpt.71
Hong, W. X. et al. Intratumoral immunotherapy for early-stage solid tumors. Clin. Cancer Res. 26, 3091–3099 (2020).
pubmed: 32071116
pmcid: 7439755
doi: 10.1158/1078-0432.CCR-19-3642
Champiat, S. et al. Intratumoral immunotherapy: From trial design to clinical practice. Clin. Cancer Res. 27, 665–679 (2021).
pubmed: 32943460
doi: 10.1158/1078-0432.CCR-20-0473
Muñoz, N. M. et al. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J. Immunother. Cancer 9, 1800 (2021).
doi: 10.1136/jitc-2020-001800
Brito-Orama, S. & Sheth, R. A. The contemporary landscape and future directions of intratumoral immunotherapy. J. Immunother. Precis. Oncol. 6, 84 (2023).
pubmed: 37214205
pmcid: 10195020
doi: 10.36401/JIPO-22-8
Mehta, A. M., Sonabend, A. M. & Bruce, J. N. Convection-enhanced delivery. Neurotherapeutics 14, 358–371 (2017).
pubmed: 28299724
pmcid: 5398992
doi: 10.1007/s13311-017-0520-4
Degen, J. W., Walbridge, S., Vortmeyer, A. O., Oldfield, E. H. & Lonser, R. R. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg. 99, 893–898 (2003).
pubmed: 14609170
doi: 10.3171/jns.2003.99.5.0893
Lidar, Z. et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J. Neurosurg. 100, 472–479 (2004).
pubmed: 15035283
doi: 10.3171/jns.2004.100.3.0472
Bell, L. K., Ainsworth, N. L., Lee, S. H. & Griffiths, J. R. MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. NMR Biomed. 24, 612–635 (2011).
pubmed: 21567513
doi: 10.1002/nbm.1720
Nelson, S. J. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 24, 734–749 (2011).
pubmed: 21538632
pmcid: 3772179
doi: 10.1002/nbm.1669
Hoult, D. I. & Richards, R. E. The signal-to-noise ratio of the nuclear magnetic resonance experiment. J. Magn. Reson. 1969(24), 71–85 (1976).
Ciobanu, L., Seeber, D. A. & Pennington, C. H. 3D MR microscopy with resolution 3.7 μm by 3.3 μm by 3.3 μm. J. Magn. Reson. 158, 178–182 (2002).
pubmed: 12419685
doi: 10.1016/S1090-7807(02)00071-X
Handwerker, J. et al. A CMOS NMR needle for probing brain physiology with high spatial and temporal resolution. Nat. Methods 17, 64–67 (2020).
pubmed: 31768059
doi: 10.1038/s41592-019-0640-3
Deborne, J., Pinaud, N. & Crémillieux, Y. Proton MRS on sub-microliter volume in rat brain using implantable NMR microcoils. NMR Biomed. 34, 10 (2021).
doi: 10.1002/nbm.4578
Deborne, J., Pinaud, N. & Crémillieux, Y. Implantable NMR microcoils in rats: A new tool for exploring tumor metabolism at sub-microliter scale?. Metabolites 11, 1456 (2021).
doi: 10.3390/metabo11030176
Lacey, M. E., Subramanian, R., Olson, D. L., Webb, A. G. & Sweedler, J. V. High-resolution NMR spectroscopy of sample Volumes from 1 nL to 10 &mL. Chem. Rev. 99, 3133–3152 (1999).
pubmed: 11749512
doi: 10.1021/cr980140f
Olson, D. L., Peck, T. L., Webb, A. G., Magin, R. L. & Sweedler, J. V. High-resolution microcoil 1H-NMR for mass-limited, nanoliter-volume samples. Science 1979(270), 1967–1970 (1995).
doi: 10.1126/science.270.5244.1967
Grobben, B., De Deyn, P. P. & Slegers, H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 310, 257–270 (2002).
pubmed: 12457224
doi: 10.1007/s00441-002-0651-7
Barth, R. F. & Kaur, B. Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J. Neurooncol. 94, 299 (2009).
pubmed: 19381449
pmcid: 2730996
doi: 10.1007/s11060-009-9875-7
Glunde, K., Bhujwalla, Z. M. & Ronen, S. M. Choline metabolism in malignant transformation. Nat. Rev. Cancer 11, 835–848 (2011).
pubmed: 22089420
pmcid: 4337883
doi: 10.1038/nrc3162
Fan, G., Sun, B., Wu, Z., Guo, Q. & Guo, Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin. Radiol. 59, 77–85 (2004).
pubmed: 14697379
doi: 10.1016/j.crad.2003.08.006
Bulik, M., Jancalek, R., Vanicek, J., Skoch, A. & Mechl, M. Potential of MR spectroscopy for assessment of glioma grading. Clin. Neurol. Neurosurg. 115, 146–153 (2013).
pubmed: 23237636
doi: 10.1016/j.clineuro.2012.11.002
Study Record|ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT01215864?tab=results (2023).
Lacal, J. C. & Campos, J. M. Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. Mol. Cancer Ther. 14, 31–39 (2015).
pubmed: 25487918
doi: 10.1158/1535-7163.MCT-14-0531
Valable, S. et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: A longitudinal in vivo and ex vivo study. NMR Biomed. 21, 1043–1056 (2008).
pubmed: 18615861
doi: 10.1002/nbm.1278
Doblas, S. et al. In vivo characterization of several rodent glioma models by 1H MRS. NMR Biomed. 25, 685–694 (2012).
pubmed: 21954105
doi: 10.1002/nbm.1785
Yao, N. W., Chang, C., Lin, H. T., Yen, C. T. & Chen, J. Y. Functional assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses. Sci. Rep. 6, 1 (2016).
De Molina, A. R. et al. Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene 21, 4317–4322 (2002).
doi: 10.1038/sj.onc.1205556
Ramírez-de-Molina, A. et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 296, 580–583 (2002).
pubmed: 12176020
doi: 10.1016/S0006-291X(02)00920-8
Hernández-Alcoceba, R. et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15, 2289–2301 (1997).
pubmed: 9393874
doi: 10.1038/sj.onc.1201414
Lacal, J. C. Choline kinase: A novel target for antitumor drugs. IDrugs 4, 419–426 (2001).
pubmed: 16015482
Kumar, M. et al. Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors. Mol. Cancer Ther. 14, 899–908 (2015).
pubmed: 25657334
pmcid: 4394035
doi: 10.1158/1535-7163.MCT-14-0775
Sanchez-Lopez, E. et al. Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death Dis. 4, 933 (2013).
doi: 10.1038/cddis.2013.453
Barua, N. U., Gill, S. S. & Love, S. Convection-enhanced drug delivery to the brain: Therapeutic potential and neuropathological considerations. Brain Pathol. 24, 117–127 (2014).
pubmed: 23944716
doi: 10.1111/bpa.12082
Elia, C. A. et al. Intracerebral injection of extracellular vesicles from mesenchymal stem cells exerts reduced Aβ plaque burden in early stages of a preclinical model of alzheimer’s disease. Cells 8, 156 (2019).
doi: 10.3390/cells8091059
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Mehta, H. J. et al. Treatment of isolated mediastinal and hilar recurrence of lung cancer with bronchoscopic endobronchial ultrasound guided intratumoral injection of chemotherapy with cisplatin. Lung Cancer 90, 542–547 (2015).
pubmed: 26477968
doi: 10.1016/j.lungcan.2015.10.009
Schad, F. et al. Intratumoral mistletoe (Viscum album L.) therapy in patients with unresectable pancreas carcinoma: A retrospective analysis. Integr. Cancer Ther. 13, 332–340 (2014).
pubmed: 24363283
doi: 10.1177/1534735413513637
Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates: Hard Cover, 466 (Springer, 2013).
Natuzzi, M. et al. Feasibility study and direct extraction of endogenous free metallic cations combining hemodialysis and chelating polymer. Sci. Rep. 11, 1–12 (2021).
doi: 10.1038/s41598-021-99462-y
Stefan, D. et al. Quantitation of magnetic resonance spectroscopy signals: The jMRUI software package. MeScT 20, 104035 (2009).
Cavassila, S., Deval, S., Huegen, C., Van Ormondt, D. & Graveron-Demilly, D. Cramér-Rao bounds: An evaluation tool for quantitation. NMR Biomed. 14, 278–283 (2001).
pubmed: 11410946
doi: 10.1002/nbm.701
Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672–679 (1993).
pubmed: 8139448
doi: 10.1002/mrm.1910300604